Combination Chemotherapy With or Without Radiation Therapy in Treating Young Patients With Favorable-Risk Hodgkin Lymphoma

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

88

Participants

Timeline

Start Date

June 5, 2009

Primary Completion Date

January 11, 2019

Study Completion Date

October 31, 2028

Conditions
Hodgkin Lymphoma
Interventions
DRUG

Stanford V Chemotherapy

The Stanford V regimen is an abbreviated, multi-agent, dose-intensive regimen that utilizes many of the most active chemotherapy agents for Hodgkin lymphoma: Vinblastine, Doxorubicin, Vincristine, Bleomycin, Mechlorethamine, Etoposide, and Prednisone

RADIATION

Radiation Therapy

Patients who achieve less than a complete response after 8 weeks of chemotherapy will receive 25.5 Gy to individual nodal sites (tailored fields) starting 2-3 weeks following completion of all chemotherapy and recovery of ANC to at least 1000.

Trial Locations (6)

38105

St. Jude Children's Research Hospital, Memphis

61637

Children's Hospital of Illinois at OSF St. Francis Medical Center, Peoria

92123

Rady Children's Hospital- San Diego, San Diego

94304

Packard Children's Hospital, Stanford University, Palo Alto

04074

Maine Children's Cancer Program (MCCP), Scarborough

02115

Dana-Farber Harvard Cancer Center, Boston

All Listed Sponsors
lead

St. Jude Children's Research Hospital

OTHER